Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Risankizumab IV and SC in Healthy Subjects
NCT07466550Phase 1Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jun 2026
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1 trial of risankizumab in plaque psoriasis and Crohn's disease (2 arms), sponsored by AbbVie Inc. Primary endpoints: Adverse Events at 155 days, Maximum Observed Serum Concentration at 155 days and 2 more. Started Jun 2026; status: recruiting.
02
Drugs
risankizumab
03
Conditions
plaque psoriasisCrohn's disease
Beyond the preview
Go deeper on NCT07466550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07466550.